The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer

Gynecologic Oncology

Volumn 100, Issue 2, 2006, Pages 412-416

  Matsumoto, Koji ^a   Katsumata, Noriyuki ^a   Yamanaka, Yasuhiro ^a   Yonemori, Kan ^a   Kohno, Tsutomu ^a   Shimizu, Chikako ^a   Andoh, Masashi ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Irinotecan; Ovarian cancer; Platinum resistant; Second line treatment; Taxanes resistant; Weekly schedule

Indexed keywords

IRINOTECAN; LOPERAMIDE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 30444431922     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.013     Document Type: Article

References (31)

1. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1 1996 1 6
2. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 9 2000 699 708
3. M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, and S. Rubin Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J. Clin. Oncol. 9 3 1991 389 393
4. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 2003 2099 2106
5. M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson, and L. Van Le Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer J. Clin. Oncol. 20 9 2002 2365 2369
6. M. Markman, K. Zanotti, K. Webster, G. Peterson, B. Kulp, and J. Belinson Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum Gynecol. Oncol. 91 3 2003 573 576
7. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J. Clin. Oncol. 16 10 1998 3345 3352
8. D.C. Bodurka, C. Levenback, J.K. Wolf, J. Gano, J.T. Wharton, and J.J. Kavanagh Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer J. Clin. Oncol. 21 2 2003 291 297
9. S. Takeuchi, K. Dobashi, S. Fujimoto, K. Tanaka, M. Suzuki, and Y. Terashima A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers Gan To Kagaku Ryoho 18 10 1991 1681 1689
10. A.N. Gordon, C.O. Granai, P.G. Rose, J. Hainsworth, A. Lopez, and C. Weissman Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer J. Clin. Oncol. 18 17 2000 3093 3100
11. P.G. Rose, J.A. Blessing, A.R. Mayer, and H.D. Homesley Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study J. Clin. Oncol. 16 2 1998 405 410
12. M. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol. Oncol. 90 3 2003 593 596
13. P. Sorensen, M. Hoyer, A. Jakobsen, H. Malmstrom, H. Havsteen, and K. Bertelsen Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma Gynecol. Oncol. 81 1 2001 58 62
14. M. Markman, T. Hakes, B. Reichman, J.L. Lewis Jr., S. Rubin, and W. Jones Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease J. Clin. Oncol. 10 2 1992 243 248
15. M.J. Piccart, J.A. Green, A.J. Lacave, N. Reed, I. Vergote, and P. Benedetti-Panici Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol. 18 6 2000 1193 1202
16. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 16 1991 4187 4191
17. S. Takeuchi, H. Takamizawa, Y. Takeda, T. Ohkawa, T. Tamaya, and K. Noda An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers Gan To Kagaku Ryoho 18 4 1991 579 584
18. Y. Ohe, Y. Sasaki, T. Shinkai, K. Eguchi, T. Tamura, and A. Kojima Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion J. Natl. Cancer Inst. 84 12 1992 972 974
19. S. Negoro, M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, and K. Matsui Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer J. Natl. Cancer Inst. 83 16 1991 1164 1168
20. M.L. Rothenberg, J.G. Kuhn, H.A. Burris III, J. Nelson, J.R. Eckardt, and M. Tristan-Morales Phase I and pharmacokinetic trial of weekly CPT-11 J. Clin. Oncol. 11 11 1993 2194 2204
21. E.K. Rowinsky, L.B. Grochow, D.S. Ettinger, S.E. Sartorius, B.G. Lubejko, and T.L. Chen Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks Cancer Res. 54 2 1994 427 436
22. D. Abigerges, G.G. Chabot, J.P. Armand, P. Herait, A. Gouyette, and D. Gandia Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients J. Clin. Oncol. 13 1 1995 210 221
23. P.J. Houghton, P.J. Cheshire, J.D. Hallman II, L. Lutz, H.S. Friedman, and M.K. Danks Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors Cancer Chemother. Pharmacol. 36 5 1995 393 403
24. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1 1981 207 214
25. G.J. Rustin, A.E. Nelstrop, P. McClean, M.F. Brady, W.P. McGuire, and W.J. Hoskins Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J. Clin. Oncol. 14 5 1996 1545 1551
26. Arbuck SG IS, Setser A, et al. The Revised Common Toxicity Criteria: Version 2.0. [cited; Available from: http://www.ctep.info.nih.gov ].
27. T. Sugiyama, T. Kamura, J. Kigawa, N. Terakawa, Y. Kikuchi, and T. Kita Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy Cancer 88 11 2000 2584 2589
28. C.S. Fuchs, M.R. Moore, G. Harker, L. Villa, D. Rinaldi, and J.R. Hecht Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J. Clin. Oncol. 21 5 2003 807 814
29. K. Yonemori, N. Katsumata, N. Yamamoto, T. Kasamatsu, T. Yamada, and R. Tsunematsu A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy Cancer 104 6 2005 1204 1212
30. Y. Yamanaka, N. Katsumata, T. Watanabe, M. Andoh, H. Mukai, and R. Kitagawa A dose finding study of irinotecan in combination with oral etoposide in patients with platinum treated advanced epithelial ovarian cancer Proc.-Am. Soc. Clin. Oncol. 21 2002 [Abstract #2521]
31. S. Nishio, T. Sugiyama, T. Shoji, R. Kitagawa, K. Ushijima, and T. Kamura Phase II study of irinotecan plus oral etoposide in patients with platinum and taxane-resistant ovarian cancer Proc.-Am. Soc. Clin. Oncol. 24 2005 [Abstract #5099]